• ArcticZymes Q2 2026 revenue rose 19% year on year to NOK 31.9 million; EBITDA climbed 90% to NOK 7.4 million.
• EBITDA margin widened 8 percentage points to 23% of revenue; net profit increased to NOK 5.3 million.
• First-half revenue increased 27% to NOK 63.7 million; EBITDA was NOK 9.0 million, versus near break-even a year earlier.
• Q2 growth was led by Molecular Tools; Biomanufacturing delivered sequential growth of 6% versus Q1.
• Management cited improved order visibility; reiterated focus on double-digit growth, GMP-grade CDMO penetration, APAC partners, RNA enzymes for IVT workflows.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArcticZymes Technologies ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260814:BIT:7718:0) on August 14, 2026, and is solely responsible for the information contained therein.